Sun Pharma: Impressive results, attractive valuation - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Oct 19, 2000 - Sun Pharma: Impressive results, attractive valuation

Sun Pharma: Impressive results, attractive valuation

Oct 19, 2000

Sun Pharma has reported results as per expectations with net profits up 41% on the back of 35% growth in the topline. The topline has been led by a 79% increase in bulk drug sales apart from a 20% increase in the formulation sales. This is due to the fact that Gujarat Lyka (which produces bulk drugs) has been amalgamated with Sun Pharma in the current year. This also explains the drop in operating margins since the contribution of bulk drugs to the total turnover has increased to 32% in the current year from 24% last year.

(Rs m)2QFY002QFY01Change
Sales 1,129 1,519 34.5%
Other Income 6 33 469.0%
Expenditure 856 1,179 37.8%
Operating Profit (EBDIT) 273 340  
Operating Profit Margin (%)24.2%22.4% 
Interest 6 (6)-198.4%
Depreciation 30 35 16.6%
Profit before Tax 243 344 41.9%
Other Adjustments   
Tax 15 22  
Profit after Tax/(Loss) 228 322 41.3%
Net profit margin (%)20.2%21.2% 
Earnings per share*19.5027.56 

However, the growth in formulation sales by 20% is impressive when seen in the light of the fact that the overall industry growth for the first five months has been in the range of 11% only. Sun Pharmaceuticals manufactures formulations in niche segments such as psychiatry, cardiovascular, gastroentology and neurology.

What is particularly encouraging for the company is the fact that formulation exports have picked up in the second quarter. Overall formulation exports in the second quarter (this includes the performance of its 99.38% subsidiary Sun Pharmaceutical Exports) have risen by almost 50% in the second quarter vis-à-vis a 39% growth in the full first half. Thus the company has successfully fine–tuned its strategy of exports of finished dosage forms.

Also, Sun has been extremely aggressive in the launch of new products in the domestic market with almost 24 new product launches in its niche areas, slated for the current year itself (10 of these have already been launched). The company derives almost 40% of its revenues from products introduced in the past five years. Consequently its exposure to revenues accruing from products under the DPCO is a relatively low 19% of domestic formulation sales.

Perhaps the only area of concern is the continuing losses of its US based affiliate Caraco Pharma, which is the company’s vehicle for launch of generics. (Sun has invested Rs 288.63 m towards equity and Rs 252.86 m towards debt in Caraco, which has registered a loss of over $ 9.5 m for the year ended December 1999.) Caraco has submitted around nine abbreviated new drug applications (ANDA) which are awaiting US FDA approval. Besides, Caraco needs further cash infusion for which it is planning to raise debt in the US market. Sun has however not provided for this dimunition in the value of its investments in the current year as the management feels that in view of the future growth potential and long term nature of investments.

The stock has come off almost 25% over the last six months to its current levels of 448. The fall in valuation is partially due to the fact that the overall valuations in the market have come down over the last one week and partially due to the concerns over its US–based affiliate Caraco’s losses. At the current valuation the stock rules at 16.25 times FY2001 earnings.

The management has already stated its intention to amalgamate Sun Pharma Exports, the company’s 99.38% subsidiary into Sun Pharma. This would add roughly another Rs 130 m to the company’s expected profits of Rs 1265 m in FY2001. The per share earnings work out to around Rs 29.85 and this implies an earning multiple of 15 at current valuations. If one were to deduct the entire losses accrued by Caraco so far (i.e. Rs 437 m) the earnings work out Rs 20.50 and the current stock price implies an earnings multiple of 22 times.

Equitymaster requests your view! Post a comment on "Sun Pharma: Impressive results, attractive valuation ". Click here!


More Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Sun Pharma's Stock Falls 4% After Its March Quarter Results (Views On News)

May 28, 2021

In the past three months, the stock has outperformed the market by gaining nearly 20%. Can it go higher?

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 3, 2021 (Close)


  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks